[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11201810848PA - Heterocyclic prolinamide derivatives - Google Patents

Heterocyclic prolinamide derivatives

Info

Publication number
SG11201810848PA
SG11201810848PA SG11201810848PA SG11201810848PA SG11201810848PA SG 11201810848P A SG11201810848P A SG 11201810848PA SG 11201810848P A SG11201810848P A SG 11201810848PA SG 11201810848P A SG11201810848P A SG 11201810848PA SG 11201810848P A SG11201810848P A SG 11201810848PA
Authority
SG
Singapore
Prior art keywords
international
amd
applicant
prevention
vancouver
Prior art date
Application number
SG11201810848PA
Inventor
Robert Gomez
Jinyue Ding
Renata Oballa
David Powell
Maxim Epifanov
Original Assignee
Orion Ophthalmology LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Ophthalmology LLC filed Critical Orion Ophthalmology LLC
Publication of SG11201810848PA publication Critical patent/SG11201810848PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)

Abstract

WO 17 / 222915 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 28 December 2017 (28.12.2017) WIP0 I PCT omit VIII Hot o Homomomim OH ois (10) International Publication Number WO 2017/222915 Al (51) International Patent Classification: CO7D 401/14 (2006.01) A61K 31/454 (2006.01) CO7D 405/14 (2006.01) A61K 31/4192 (2006.01) C07D 409/14 (2006.01) (21) International Application Number: PCT/US2017/037768 (22) International Filing Date: 15 June 2017 (15.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/352,963 21 June 2016 (21.06.2016) US (71) Applicant: INCEPTION 4, INC. [US/US]; 5871 Oberlin Drive, Suite 100, San Diego, CA 92121 (US). (72) Inventors: GOMEZ, Robert; 3344 Mt. Seymour Park- way, North Vancouver, BC V7H 1G3 (CA). DING, Jinyue; 17-9088 Halston Court, Burnaby, BC V3N 0A7 (CA). OBALLA, Renata, Marcella; 1973 Custer Court, Co- quitlam, BC V3J 6R2 (CA). POWELL, David, Andrew; 1781 Napier Street, Vancouver, BC V5L 2N1 (CA). EPI- FANOV, Maxim; 2460 Trutch Street, Vancouver, BC V6K 4H4 (CA). (74) Agent: MALLON, Joseph, J.; Knobbe Martens Olson & Bear LLP, 2040 Main Street, Fourteenth Floor, Irvine, CA 92614 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) (54) Title: HETEROCYCLIC PROLINAMIDE DERIVATIVES (57) : This invention is directed to novel heterocyclic prolinamide derivatives of Formula (I), and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye. These diseases include dry-AMD, wet-AMD, geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degenera- tion of retinal or photoreceptor cells. The invention disclosed herein is further directed to methods of prevention, slowing the progress of, and treatment of dry-AMD, wet-AMD, and geographic at- rophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and de- generation of retinal or photoreceptor cells, comprising: administration of a therapeutically effective amount of compound of the invention. The compounds of the invention are inhibitors of HTRA1. Thus, the compounds of the invention are useful in the prevention and treatment of a wide range of diseases mediated (in whole or in part) by HTRA1. The compounds of the invention are also useful for inhibiting HTRA1 protease activity in an eye or locus of an arthritis or related condition. H (I)
SG11201810848PA 2016-06-21 2017-06-15 Heterocyclic prolinamide derivatives SG11201810848PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662352963P 2016-06-21 2016-06-21
PCT/US2017/037768 WO2017222915A1 (en) 2016-06-21 2017-06-15 Heterocyclic prolinamide derivatives

Publications (1)

Publication Number Publication Date
SG11201810848PA true SG11201810848PA (en) 2019-01-30

Family

ID=60783554

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201810848PA SG11201810848PA (en) 2016-06-21 2017-06-15 Heterocyclic prolinamide derivatives

Country Status (21)

Country Link
US (2) US11377439B2 (en)
EP (2) EP4257191A3 (en)
JP (2) JP7179721B2 (en)
KR (2) KR20230153504A (en)
CN (2) CN114685453A (en)
AU (2) AU2017282651B2 (en)
BR (1) BR112018076614A2 (en)
CA (1) CA3025253A1 (en)
DK (1) DK3472149T3 (en)
EA (1) EA201990069A1 (en)
ES (1) ES2971784T3 (en)
FI (1) FI3472149T3 (en)
HU (1) HUE064412T2 (en)
IL (1) IL263284B (en)
MX (1) MX2018016189A (en)
PH (1) PH12018502696A1 (en)
PL (1) PL3472149T3 (en)
PT (1) PT3472149T (en)
SG (1) SG11201810848PA (en)
UA (1) UA124672C2 (en)
WO (1) WO2017222915A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10526315B2 (en) 2016-06-21 2020-01-07 Orion Ophthalmology LLC Carbocyclic prolinamide derivatives
UA124672C2 (en) * 2016-06-21 2021-10-27 Оріон Офтальмолоджі Ллс Heterocyclic prolinamide derivatives

Family Cites Families (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0315574A3 (en) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin inhibitors
US5023236A (en) 1988-04-07 1991-06-11 Corvas, Inc. Factor VII/VIIA active site inhibitors
DE3827340A1 (en) 1988-08-12 1990-02-15 Hoechst Ag USE OF (ALPHA) -AMINOBORONIC ACID DERIVATIVES FOR THE PROPHYLAXIS AND TREATMENT OF VIRUS DISEASES
US5225402A (en) 1989-02-10 1993-07-06 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
CA2077665A1 (en) 1990-03-05 1991-09-06 Robert Siman Chymotrypsin-like proteases and their inhibitors
GB9017694D0 (en) 1990-08-13 1990-09-26 Sandoz Ltd Improvements in or relating to organic chemistry
GB9024129D0 (en) 1990-11-06 1990-12-19 Thrombosis Research Trust Inhibitors and substrates of thrombin
US5712267A (en) 1991-06-04 1998-01-27 Sankyo Company,. Limited Carbapenem derivatives, their preparation and their use as antibiotics
JP2668003B2 (en) 1992-06-12 1997-10-27 ファイザー インク． Inhibitors for angiotensin I chymase, including human heart chymase
US5208313A (en) 1992-07-16 1993-05-04 Surface Coatings, Inc. Waterproof breathable polyurethane membranes and porous substrates protected therewith
IL109319A0 (en) 1993-04-27 1994-07-31 Du Pont Merck Pharma Amidino and guanidino substituted boronic acid compounds
US5658885A (en) 1993-04-27 1997-08-19 The Dupont Merck Pharmaceutical Company Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes
WO1994025051A1 (en) 1993-04-30 1994-11-10 Merck & Co., Inc. Thrombin inhibitors
US5672582A (en) 1993-04-30 1997-09-30 Merck & Co., Inc. Thrombin inhibitors
DE69429527T2 (en) 1993-10-01 2002-07-18 Merrell Dow Pharmaceuticals Inc., Cincinnati INHIBITORS OF BETA AMYLOID PROTEIN PRODUCTION
IL111175A0 (en) 1993-10-07 1994-12-29 Du Pont Merck Pharma Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them
IL111176A0 (en) 1993-10-07 1994-12-29 Du Pont Merck Pharma Dipeptide boronic acid inhibitors of trypsin-like enzymes and pharmaceutical compositions containing them
GB9401483D0 (en) 1994-01-26 1994-03-23 Sandoz Ltd Organic compounds
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
EP0793673A1 (en) 1994-11-24 1997-09-10 Takeda Chemical Industries, Ltd. Alpha-ketoamide derivatives as cathepsin l inhibitor
US5919765A (en) 1995-06-07 1999-07-06 Cor Therapeutics, Inc. Inhibitors of factor XA
TW442452B (en) 1996-03-01 2001-06-23 Akzo Nobel Nv Serine protease inhibitors having an alkynylamino side chain
IL120311A (en) 1996-03-01 2001-10-31 Akzo Nobel Nv Serine protease inhibitors and pharmaceutical compositions containing them
NZ335276A (en) 1996-10-18 2000-09-29 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
DE69827956T2 (en) 1997-08-11 2005-04-14 Boehringer Ingelheim (Canada) Ltd., Laval PEPTIDE ANALOGUE WITH INHIBITORAL EFFECT ON HEPATITIS C
DE19746468A1 (en) 1997-10-21 1999-04-22 Henkel Kgaa Mascara for temporary coloring of human hair
WO2000008134A2 (en) 1998-08-03 2000-02-17 Novartis Ag HUMAN HtrA SERINE PROTEASE
EP1153301A1 (en) 1999-02-19 2001-11-14 University Of Iowa Research Foundation Diagnostics and therapeutics for arterial wall disruptive disorders
AU5788800A (en) 1999-07-07 2001-01-22 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
AU2002222933A1 (en) 2000-07-13 2002-01-30 Millennium Pharamaceuticals, Inc. Inhibitors of factor xa
AR029851A1 (en) 2000-07-21 2003-07-16 Dendreon Corp NEW PEPTIDES AS INHIBITORS OF NS3-SERINA PROTEASA DEL VIRUS DE HEPATITIS C
MXPA03000627A (en) * 2000-07-21 2004-07-30 Schering Corp Novel peptides as ns3-serine protease inhibitors of hepatitis c virus.
EP1303487A4 (en) 2000-07-21 2005-11-23 Schering Corp Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
WO2002018335A1 (en) 2000-08-28 2002-03-07 Yamanouchi Pharmaceutical Co., Ltd. Cyclic amine derivatives
SV2003000617A (en) 2000-08-31 2003-01-13 Lilly Co Eli INHIBITORS OF PROTEASA PEPTIDOMIMETICA REF. X-14912M
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
FR2816509B1 (en) 2000-11-15 2004-02-06 Sod Conseils Rech Applic ASSOCIATION OF CALPAIN INHIBITORS AND OXYGEN REACTIVE TRAPS
US7172874B2 (en) 2001-04-30 2007-02-06 The Cleveland Clinic Foundation Diagnostic methods for age related macular degeneration
US7244815B2 (en) 2001-05-23 2007-07-17 The Curators Of The University Of Missouri Attachment and elaboration strategies for inverse peptide synthesis
WO2002094857A1 (en) 2001-05-23 2002-11-28 The Curators Of The University Of Missouri Inverse solid phase synthesis of peptides
WO2002096933A1 (en) 2001-05-30 2002-12-05 Novartis Ag 2-{[n-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl]-amino}-alkylboronic acid derivatives
NZ575692A (en) 2002-04-11 2009-10-30 Vertex Pharma Inhibitors of Serine Proteases, Particularly Hepatitis C Virus NS3-NS4 Protease
PL215228B1 (en) 2002-05-20 2013-11-29 Bristol Myers Squibb Co Hepatitis c virus inhibitors
JP2006506442A (en) 2002-07-09 2006-02-23 ポイント セラピューティクス， インコーポレイテッド Boroproline compound combination therapy
US20050282757A1 (en) 2002-09-09 2005-12-22 Trigen Limited Peptide boronic acid compounds useful in anticoagulation
US20050119226A1 (en) 2003-09-09 2005-06-02 Trigen Limited Methods for synthesizing organoboronic compounds and products thereof
US20050176651A1 (en) 2002-09-09 2005-08-11 Trigen Limited Peptide boronic acids useful in making salts thereof
AU2003263328A1 (en) 2002-09-09 2004-03-29 Trigen Limited Boronic acid salts useful in parenteral formulations for selective thrombin inhibition
EP1618087B1 (en) 2003-01-08 2012-06-13 Novartis Vaccines and Diagnostics, Inc. Antibacterial agents
WO2004103270A2 (en) 2003-04-02 2004-12-02 Suntory Pharmaceutical Research Laboratories Llc Compounds and methods for treatment of thrombosis
TW200510391A (en) 2003-04-11 2005-03-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
EP2332935A1 (en) 2003-04-11 2011-06-15 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US7273851B2 (en) 2003-06-05 2007-09-25 Enanta Pharmaceuticals, Inc. Tri-peptide hepatitis C serine protease inhibitors
WO2004113365A2 (en) * 2003-06-05 2004-12-29 Enanta Pharmaceuticals, Inc. Hepatitis c serine protease tri-peptide inhibitors
PE20050251A1 (en) 2003-07-18 2005-04-13 Vertex Pharma SERINE PROTEASE INHIBITORS, ESPECIALLY HCV PROTEASE NS3-NS4A
UY28500A1 (en) 2003-09-05 2005-04-29 Vertex Pharma INHIBITORS OF SERINE PROTEASES, IN PARTICULAR PROTEASA NS3-NS4A HCV.
CA2538791A1 (en) 2003-09-18 2005-03-31 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
BRPI0506494A (en) 2004-01-30 2007-02-13 Schering Ag silinane compounds as cysteine protease inhibitors
WO2005077969A2 (en) 2004-02-04 2005-08-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
KR101292707B1 (en) 2004-02-23 2013-08-02 트러스티즈 오브 터프츠 칼리지 Inhibitors of dipeptidylpeptidase iv
GB0405272D0 (en) 2004-03-09 2004-04-21 Trigen Ltd Compounds
GB0405280D0 (en) 2004-03-09 2004-04-21 Trigen Ltd Compounds
GB0405267D0 (en) 2004-03-09 2004-04-21 Trigen Ltd Compounds
WO2005105829A2 (en) 2004-04-30 2005-11-10 Theraptosis S.A. Caspase-2 inhibitors and their biological applications
MXPA06014969A (en) 2004-07-02 2007-02-08 Genentech Inc Inhibitors of iap.
FR2873695A1 (en) 2004-07-30 2006-02-03 Palumed Sa HYBRID MOLECULES QA OR Q IS AMINOQUINOLINE AND A IS AN ANTIBIOTIC OR A RESISTANCE INHIBITOR), THEIR SYNTHESIS AND USES THEREOF AS ANTIBACTERIAL AGENT
CA2577987A1 (en) 2004-08-25 2006-03-02 Santhera Pharmaceuticals (Schweiz) Ag Alpha-keto carbonyl calpain inhibitors
WO2006021413A1 (en) 2004-08-25 2006-03-02 Santhera Pharmaceuticals (Schweiz) Ag Alpha-keto carbonyl calpain inhibitors
WO2006059082A1 (en) 2004-11-30 2006-06-08 Trigen Limited Oxidised lipids as reversal agents for boronic acid drugs
WO2006059083A1 (en) 2004-11-30 2006-06-08 Trigen Limited Neutralising agents for boronic acid drugs
ATE526421T1 (en) * 2005-02-14 2011-10-15 Univ Iowa Res Found METHODS AND REAGENTS FOR THE TREATMENT AND DIAGNOSIS OF AGE-RELATED MACULAR DEGENERATION
CN101160412A (en) * 2005-02-14 2008-04-09 爱荷华大学研究基金会 Methods and reagents for treatment and diagnosis of age-related macular degeneration
US20060252698A1 (en) 2005-04-20 2006-11-09 Malcolm Bruce A Compounds for inhibiting cathepsin activity
US20060276405A1 (en) 2005-06-02 2006-12-07 Schering Corporation Methods for treating hepatitis C
WO2006130552A2 (en) 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis c virus
WO2006130553A2 (en) 2005-06-02 2006-12-07 Schering Corporation Hcv protease inhibitors
US20060276407A1 (en) 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis C virus
US20060275366A1 (en) 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation
US7608592B2 (en) 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
WO2007016476A2 (en) 2005-08-01 2007-02-08 Phenomix Corporation Hepatitis c serine protease inhibitors and uses therefor
JP2009524681A (en) 2006-01-27 2009-07-02 フェノミックス コーポレーション Hepatitis C virus serine protease inhibitor and uses therefor
WO2007095250A2 (en) 2006-02-13 2007-08-23 The Cleveland Clinic Foundation Compositions and methods for inhibiting optic nerve damage
US20070212865A1 (en) 2006-03-08 2007-09-13 Craig Amrine Method for planarizing vias formed in a substrate
WO2007120595A2 (en) 2006-04-11 2007-10-25 Novartis Ag Amines for the treatment of hcv
US7825152B2 (en) 2006-04-11 2010-11-02 Novartis Ag Organic compounds and their uses
WO2007146695A1 (en) 2006-06-06 2007-12-21 Enanta Pharmaceuticals, Inc. Acyclic oximyl hepatitis c protease inhibitors
WO2007146831A2 (en) 2006-06-08 2007-12-21 Cylene Pharmaceuticals, Inc. Quinolone analogs derivatized with sulfonic acid, sulfonate or sulfonamide
US20100056495A1 (en) 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
MX2009000909A (en) 2006-07-26 2009-02-04 Univ Yale Diagnosis and treatment of age related macular degeneration.
EP2081596A4 (en) 2006-10-06 2010-07-21 Univ Utah Res Found Method of detecting ocular diseases and pathologic conditions and treatment of same
WO2008094370A2 (en) 2006-12-22 2008-08-07 University Of Utah Research Foundation Method of detecting ocular diseases and pathologic conditions and treatment of same
WO2008086053A1 (en) 2007-01-03 2008-07-17 Virobay, Inc. Hcv inhibitors
WO2008089485A2 (en) 2007-01-19 2008-07-24 The Cleveland Clinic Foundation Carboxyethylpyrrole compounds and methods of their production
US7972787B2 (en) 2007-02-16 2011-07-05 Massachusetts Eye And Ear Infirmary Methods for detecting age-related macular degeneration
EP2495249A1 (en) 2007-02-26 2012-09-05 Achillion Pharmaceuticals, Inc. Tertiary amine substituted peptides useful as inhibitors of HCV replication
WO2008112798A1 (en) 2007-03-12 2008-09-18 Mayo Foundation For Medical Education And Research Treating pre-eclempsia and cardiovascular diseases
MX2009010205A (en) 2007-03-23 2009-10-19 Schering Corp P1-nonepimerizable ketoamide inhibitors of hcv ns3 protease.
WO2008118848A1 (en) 2007-03-23 2008-10-02 Trustees Of Tufts College N-substituted peptidomimetic inhibitors of dipeptidylpeptidase iv
EA200971041A1 (en) 2007-05-10 2010-08-30 Интермьюн, Инк. NEW PEPTIDE HEPATITIS C VIRUS REPLICATION INHIBITORS
TW200911290A (en) 2007-07-02 2009-03-16 Alcon Res Ltd RNAI-mediated inhibition of HTRA1 for treatment of macular degeneration
WO2009006473A2 (en) 2007-07-05 2009-01-08 Trustees Of Tufts College Pro-soft polypeptide proteasome inhibitors, and methods of use thereof
KR101831674B1 (en) 2007-08-06 2018-02-23 밀레니엄 파머슈티컬스 인코퍼레이티드 Proteasome inhibitors
WO2009046405A2 (en) 2007-10-05 2009-04-09 University Of Utah Research Foundation Antibodies to htra1 and methods of using the same
US7683636B2 (en) 2007-10-26 2010-03-23 Honeywell International Inc. Structure for capacitive balancing of integrated relative humidity sensor
CA2704809A1 (en) 2007-11-01 2009-05-07 University Of Iowa Research Foundation Rca locus analysis to assess susceptibility to amd and mpgnii
HUE028064T2 (en) 2007-12-03 2016-11-28 Obe Therapy Biotechnology Boropeptide inhibitors of enteropeptidase and their uses in treatment of obesity, overweight and/or diseases associated with an abnormal fat metabolism
US8193346B2 (en) 2007-12-06 2012-06-05 Enanta Pharmaceuticals, Inc. Process for making macrocyclic oximyl hepatitis C protease inhibitors
CN101969973B (en) 2008-02-07 2015-07-22 维罗贝股份有限公司 Inhibitors of cathepsin B
US20110110857A1 (en) 2008-03-06 2011-05-12 Roberto Petracca Mutant forms of chlamydia htra
CN101638414B (en) 2008-07-30 2014-01-08 江苏先声药物研究有限公司 Peptidyl boronic acid, ester compound thereof, preparation method of peptidyl boronic acid and ester compound thereof, and use of peptidyl boronic acid and ester compound thereof
CN102177152A (en) 2008-08-11 2011-09-07 哈佛大学校长及研究员协会 Halofuginone analogs for inhibition of tRNA synthetases and uses thereof
AR075090A1 (en) 2008-09-29 2011-03-09 Millennium Pharm Inc ACID DERIVATIVES 1-AMINO-2-CYCLLOBUTILETILBORONICO PROTEOSOMA INHIBITORS, USEFUL AS ANTI-BANKER AGENTS, AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM.
PL2540843T3 (en) 2008-11-05 2014-12-31 Genentech Inc Genetic polymorphisms in age-related macular degeneration
WO2010132459A2 (en) 2009-05-11 2010-11-18 Cleveland Clinic Foundation Biomarkers for assessment of age-related macular degeneration
CN101928329B (en) 2009-06-19 2013-07-17 北京大学 Tripeptide boric acid (ester) compound and preparation method and application thereof
WO2011053774A1 (en) 2009-10-30 2011-05-05 Alcon Research, Ltd. Single nucleotide polymorphisms and genes associated with age-related macular degeneration
US20110152246A1 (en) 2009-12-18 2011-06-23 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
WO2011094426A1 (en) 2010-01-29 2011-08-04 The United State Of America, As Represented By The Secretary, Department Of Health & Human Services Caspase inhibitors
US9359398B2 (en) 2010-03-01 2016-06-07 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
US20110312996A1 (en) 2010-05-17 2011-12-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
WO2011156632A2 (en) 2010-06-09 2011-12-15 Georgetown University Compositions and methods of treatment for tumors in the nervous system
WO2012040242A1 (en) 2010-09-22 2012-03-29 Intermune, Inc. Substituted proline inhibitors of hepatitis c virus replication
WO2012078540A1 (en) 2010-12-08 2012-06-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulating immune cell activity using cytokine-induced src homology 2 and/or high temperature requirement a-1
TWI617559B (en) 2010-12-22 2018-03-11 江蘇恆瑞醫藥股份有限公司 2-arylimidazo[1,2-b]pyridazine, 2-phenylimidazo[1,2-a]pyridine, and 2-phenylimidazo[1,2-a]pyrazine derivatives
WO2012125872A2 (en) 2011-03-15 2012-09-20 University Of Utah Research Foundation Methods of diagnosing and treating vascular associated maculopathy and symptoms thereof
CN102807607B (en) 2011-07-22 2013-10-23 爱博新药研发(上海)有限公司 Fused ring heterocycle compound for restraining hepatitis c virus, midbody and application of fused ring heterocycle compound
PT2753334T (en) 2011-08-30 2022-11-03 Tufts College Fap-activated proteasome inhibitors for treating solid tumors
SG11201401477XA (en) 2011-10-14 2014-07-30 Genentech Inc ANTI-HtrA1 ANTIBODIES AND METHODS OF USE
EP2768517A4 (en) 2011-10-17 2015-03-11 Enanta Pharm Inc Hepatitis c virus inhibitors
US8549645B2 (en) 2011-10-21 2013-10-01 Mcafee, Inc. System and method for detection of denial of service attacks
KR20140132367A (en) 2012-02-16 2014-11-17 알큐엑스 파마슈티컬스, 인크. Linear peptide antibiotics
WO2013149306A1 (en) 2012-04-05 2013-10-10 Prince Henry's Institute Of Medical Research Antibodies to htra3
US20150211065A1 (en) 2012-09-14 2015-07-30 University Of Utah Research Foundation Methods of predicting the development of amd based on chromosome 1 and chromosome 10
SG10201803157XA (en) 2013-05-01 2018-05-30 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-122
WO2015042447A1 (en) 2013-09-20 2015-03-26 Isis Pharmaceuticals, Inc. Targeted therapeutic nucleosides and their use
CA2924527C (en) 2013-09-20 2022-07-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Compounds for treating prostate cancer
JP6337750B2 (en) 2013-11-22 2018-06-06 小野薬品工業株式会社 Compound
US9981942B2 (en) 2013-12-20 2018-05-29 Laboratorios Del Dr. Esteve S.A. Piperidine derivatives having multimodal activity against pain
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
WO2016100555A1 (en) 2014-12-18 2016-06-23 Inception 4, Inc. Boronic acid derivatives and uses thereof
AR103742A1 (en) 2015-02-25 2017-05-31 Hoffmann La Roche DERIVATIVES OF TRIFLUOROMETILPROPANAMIDA
FR3034709B1 (en) 2015-04-09 2017-04-14 Michelin & Cie PNEUMATIC HAVING AN ELECTRONIC DEVICE
EP3294718B1 (en) 2015-05-11 2020-04-29 H. Hoffnabb-La Roche Ag New difluoroketamide derivatives
AU2016344399B2 (en) 2015-10-30 2019-03-28 Genentech, Inc. Anti-HtrA1 antibodies and methods of use thereof
WO2017148964A1 (en) 2016-03-04 2017-09-08 F. Hoffmann-La Roche Ag New trifluoromethylpropanamide derivatives as htra1 inhibitors
CN108699105A (en) 2016-03-04 2018-10-23 豪夫迈·罗氏有限公司 Novel difluoro keto acyl amine derivative as HTRA1 inhibitor
EP3472130B1 (en) 2016-06-21 2022-02-16 Orion Ophthalmology LLC Aliphatic prolinamide derivatives
UA124672C2 (en) 2016-06-21 2021-10-27 Оріон Офтальмолоджі Ллс Heterocyclic prolinamide derivatives
US10526315B2 (en) * 2016-06-21 2020-01-07 Orion Ophthalmology LLC Carbocyclic prolinamide derivatives
CA3026855A1 (en) 2016-07-01 2018-01-04 F. Hoffmann-La Roche Ag Antisense oligonucleotides for modulating htra1 expression
WO2018015240A1 (en) 2016-07-18 2018-01-25 F. Hoffmann-La Roche Ag New difluoroketamide derivatives as htra1 inhibitors
CN109563084A (en) 2016-08-23 2019-04-02 豪夫迈·罗氏有限公司 Novel trifluoromethyl propanamide derivative as HTRA1 inhibitor
CN109661389A (en) 2016-08-23 2019-04-19 豪夫迈·罗氏有限公司 Novel difluoro keto acyl amine derivative as HTRA1 inhibitor
WO2018206816A1 (en) 2017-05-12 2018-11-15 Universität Duisburg-Essen Tailored cyclodepsipeptides as potent non-covalent serine protease inhibitors

Also Published As

Publication number Publication date
ES2971784T3 (en) 2024-06-07
CN109476637A (en) 2019-03-15
EP4257191A2 (en) 2023-10-11
AU2017282651B2 (en) 2021-08-12
EP3472149A4 (en) 2020-01-15
JP7179721B2 (en) 2022-11-29
US20190322645A1 (en) 2019-10-24
US11377439B2 (en) 2022-07-05
HUE064412T2 (en) 2024-03-28
FI3472149T3 (en) 2023-11-09
CA3025253A1 (en) 2017-12-28
JP2019519611A (en) 2019-07-11
PH12018502696A1 (en) 2019-11-04
EA201990069A1 (en) 2019-06-28
PL3472149T3 (en) 2024-02-12
AU2017282651A1 (en) 2018-12-06
EP4257191A3 (en) 2023-11-22
KR20190011322A (en) 2019-02-01
UA124672C2 (en) 2021-10-27
AU2021261935A1 (en) 2021-12-02
CN114685453A (en) 2022-07-01
MX2018016189A (en) 2019-06-10
IL263284A (en) 2018-12-31
US20220267306A1 (en) 2022-08-25
KR102595723B1 (en) 2023-10-27
EP3472149B1 (en) 2023-08-30
PT3472149T (en) 2023-11-23
DK3472149T3 (en) 2023-11-27
WO2017222915A1 (en) 2017-12-28
BR112018076614A2 (en) 2019-04-02
JP2023027074A (en) 2023-03-01
KR20230153504A (en) 2023-11-06
EP3472149A1 (en) 2019-04-24
IL263284B (en) 2021-05-31
AU2021261935B2 (en) 2023-10-19
CN109476637B (en) 2022-02-01

Similar Documents

Publication Publication Date Title
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201908598PA (en) Compounds useful in the treatment or prevention of a prmt5-mediated disorder
SG11201907544VA (en) Jak inhibitors containing a 4-membered heterocyclic amide
SG11201803757UA (en) N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases
SG11201908670SA (en) Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators
SG11201811712QA (en) 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
SG11201908179UA (en) Aryl cyclopropyl-amino-isoquinolinyl amide compounds
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201408133TA (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
SG11201908517XA (en) Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201408232RA (en) 1,2,4-triazine-6-carboxamide kinase inhibitors
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201811559WA (en) Cancer treatment combinations
SG11201909245PA (en) Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201909793YA (en) AMIDE DERIVATIVES AS Nav1.7 and Nav1.8 BLOCKERS
SG11201408240TA (en) Treatment of motor and movement disorder side effects associated with parkinson's disease treatments
SG11201903312VA (en) Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201407575PA (en) 5-amino[1,4]thiazines as bace 1 inhibitors
SG11201804885TA (en) Monomaleimide-functionalized platinum compounds for cancer therapy
SG11201908322WA (en) Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
SG11201901850XA (en) Dopamine-b-hydroxylase inhibitors